Genexpressionstests zur Prognose und Prädiktion

Abstract

Malignant breast tumors are not only characterized by conventional clinicopathological features such as tumor size, estrogen receptor status, grading and nodal status but also according to their individual gene expression profile. Different molecular subtypes lead to different outcomes of the disease, concerning progression-free and overall survival. Based on this evidence various genomic assays have been introduced into clinical practice. In Germany, there are three assays currently available: Oncotype DX® (Genomic Health), Endopredict® (Sividon) and Prosigna® (NanoString). This article provides an overview of these three tests and discusses similarities and differences between them, especially concerning their impact on adjuvant treatment decisions, and their ability to predict chemotherapy benefit or late metastases. Findings are put into the clinical context of management of early breast cancer.